Question explored with the scientific record
Are there any safe drugs to build bone in osteoporosis
The short version: the drugs that actually build new bone are teriparatide and abaloparatide, but "safe" is a high bar these studies do not clear.
The anabolic drugs are the only ones that truly build bone. Teriparatide raised lumbar spine bone density by about 9% over roughly two years in a large randomized trial, and cut vertebral fractures from about 15 in 100 to about 5 in 100 in women 75 and older [1]. Abaloparatide cut vertebral fractures from about 4 in 100 to under 1 in 100 in an 18-month trial [6]. The bisphosphonates and denosumab mostly slow bone loss, not build it, though they do reduce fractures [4][5].
The safety record is the problem. Teriparatide carries a black-box warning for osteosarcoma, a bone cancer seen in animal studies [3]. The trials here ran only 18 to 36 months, so long-term cancer risk in humans is simply unknown [1][6]. Zoledronic acid raised atrial fibrillation cases from 20 to 50 in a 7,700-person trial, and deaths from 112 to 130 [5]. Denosumab causes hypocalcemia in about 16 in 100 patients in one community study, and stopping it triggers rapid bone loss [7][8].
| Drug | Vertebral fractures (drug vs placebo) | Bone density gain (lumbar spine) | Key safety signal |
|---|---|---|---|
| Teriparatide | 5% vs 15% [1] | ~9% [1] | Osteosarcoma warning [3] |
| Abaloparatide | 0.6% vs 4.2% [6] | ~5-7% [2] | Palpitations, nausea [6] |
| Zoledronic acid | 3.3% vs 10.9% [5] | ~6.7% [5] | Atrial fibrillation, death [5] |
| Denosumab | Not reported vs placebo | ~20% over 9 years [8] | Hypocalcemia, rebound loss [7][8] |
None of these trials compared against a truly untreated group for long enough to catch rare harms. The fracture benefits are real for high-risk women, but "safe" is a claim the evidence does not support beyond a few years.
My call: these drugs meaningfully reduce fractures in high-risk patients, but long-term safety is unproven, and the burden of proof for "safe" has not been met. Confidence: moderate on benefit, low on long-term safety.
Sources used 8
-
Safety and Efficacy of Teriparatide in Elderly Women with Established Osteoporosis: Bone Anabolic Therapy from a Geriatric Perspective
Age does not alter the safety or efficacy of teriparatide in postmenopausal osteoporosis: in women 75 and older, teriparatide produced similar bone turnover marker responses, lumbar spine and femoral neck BMD gains, and reductions in vertebral/nonvertebral fractures as in younge…
DOI: 10.1111/j.1532-5415.2006.00695.x -
Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis
This study evaluates the effects of abaloparatide, a synthetic peptide analog of parathyroid hormone-related protein, on bone mineral density in postmenopausal women with osteoporosis, demonstrating significant increases in lumbar spine, femoral neck, and total hip BMD compared …
DOI: 10.1210/jc.2014-3718 -
Osteoporosis – a current view of pharmacological prevention and treatment
This open-access narrative review summarizes the current pharmacological approaches to prevention and treatment of osteoporosis, detailing mechanisms and clinical agents (anti-resorptives and anabolic therapies), monitoring strategies, guidelines, safety concerns, and emerging t…
DOI: 10.2147/DDDT.S31504 -
Bisphosphonates in Postmenopausal Women with Osteoporosis to Prevent Future Fractures
A review of eight randomized placebo-controlled trials concluded that bisphosphonate therapy in postmenopausal women with osteoporosis increases bone mineral density and, in four of five fracture-reporting trials, reduces future fracture risk, despite one conflicting trial.
DOI: 10.23880/jobd-16000179 -
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
A multicenter, randomized, double-blind trial in postmenopausal women with osteoporosis showed that annual infusions of zoledronic acid (5 mg) over 3 years significantly reduced vertebral, hip, and other fractures, improved bone density and turnover markers, and had a generally …
DOI: 10.1056/NEJMoa067312 -
The Role of Novel Bone Forming Agents in the Treatment of Osteoporosis
A narrative pharmacologic review comparing the two novel bone-forming agents romosozumab and abaloparatide for osteoporosis, summarizing their mechanisms, pivotal 12–18 month trials (FRAME/ARCH for romosozumab; ACTIVE/ACTIVExtend for abaloparatide), sequential therapy implicatio…
DOI: 10.1177/0897190020961227 -
Incidence of Hypocalcemia in Patients with Post-Menopausal Osteoporosis or Cancer Skeletal Related Events after Denosumab in Comparison to Zoledronic Acid in a Community Hospital Setting
A retrospective cohort study in a community hospital comparing hypocalcemia incidence after denosumab versus zoledronic acid in postmenopausal osteoporosis or cancer skeletal-related events, finding higher hypocalcemia with denosumab and recommending larger prospective monitorin…
DOI: 10.4172/2329-6887.1000176 -
Experience of long-term use of denosumab in women with osteoporosis and various concomitant diseases
In a retrospective single-center study of 148 women with osteoporosis, long-term denosumab therapy increased bone mineral density in the spine and femoral neck and reduced CTx levels in both treatment-naive patients and those previously treated with antiresorptive therapy.
DOI: 10.14341/osteo12922